Advertisement

Topics

De Novo Pharmaceuticals Ltd Company Profile

15:52 EDT 25th June 2018 | BioPortfolio

The volume of structural protein data that will emerge in the next few years will serve as a driver that transforms the pharmaceutical industry. Over the next decade it is predicted that the high-resolution 3-D structure of all proteins that precisely define the biological space of human, pathogenic organisms and plant proteomes will be available. As this flood of data on proteins becomes available, De Novo is centrally positioned to efficiently link biological space to chemical space.

Location

Compass HouseVision ParkHiston
Cambridge
Cambridgeshire
CB4 9ZR
United Kingdom

Contact

Phone: 44 (0)1223 238000
Email: info@denovopharma.com


News Articles [964 Associated News Articles listed on BioPortfolio]

Novo Nordisk: Passende Übernahme

Die Analysten der UBS bestätigen die Kaufempfehlung für die Aktien von Novo Nordisk aus Dänemark. Das Kursziel für die Papiere von Novo Nordisk sehen die Experten weiter bei 370,00 DKK. Die Dänen...

Ablynx Rejects Novo Nordisk’s $3.1 Billion Acquisition Proposal

GHENT, Belgium, 8 January 2018 – Ablynx NV (Euronext Brussels and Nasdaq: ABLX) (“Ablynx” or the “Company”) today confirmed that on December 22, 2017 it received an unsolicited condition...

Veloxis Pharmaceuticals Releases Annual Report for 2017

Highlights Veloxis Pharmaceuticals A/S agreed to amend and restate the terms of its previously announced loan and security agreement with Lundbeckfond Invest A/S and Novo Read more...

Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk

Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth more than what Novo offered in the first place. Early this morning, Novo Nordisk...

Novo Holdings Pumps €135M into New Antibiotic Development to Fight Resistance

Novo Holdings has launched a $165M (€135M) impact fund to support companies that are developing new drugs to overcome antibiotic resistance. Novo Holdings is the venture capital arm of the Danish b...

Novo Nordisk Aktie: Novo Nordisk nimmt neue Märkte ins Visier!

Liebe Leser, Novo Nordisk ist den meisten Anlegern aufgrund seiner Diabetes-Medikamente bekannt. Bekanntlich ist es jedoch nie eine gute Idee, all sein Geld auf ein einziges Pferd zu setzen. Deshal...

Quotidian Technical Highlights on Selected Drug Makers Stocks -- Novo Nordisk, Sucampo Pharma, ...

www.wallstequities.com/registration Novo Nordisk On Thursday, shares in Bagsvaerd, Denmarkheadquartered Novo Nordisk A/S recorded a trading volume of 2.22 million shares, which was above their R...

Sanofi outbids Novo with €45 per share offer for Ablynx, total of €3.8bn

Public Belgian biotech Ablynx NV agreed to be acquired by Sanofi, which offered €45 per share ($59.92; a 37% premium) for a fully diluted equity value of €3.8bn ($5.1bn). The deal trumps an offer ...

Drugs and Medications [296 Associated Drugs and Medications listed on BioPortfolio]

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Novo Nordisk]

NOVOLIN N Human Insulin Isophane Suspension (recombinant DNA origin) 100 units/mL

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Myfortic [Novartis Pharmaceuticals Corporation]

Myfortic (mycophenolic   acid*) delayed-release tablets *as mycophenolate   sodium Rx only Prescribing Information

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

PubMed Articles [394 Associated PubMed Articles listed on BioPortfolio]

De Novo Synthesis of Benzannelated Heterocycles.

Benzannelated heterocycles such as indoles and indazoles are prominent structural motifs found in natural products, pharmaceuticals and agrochemicals. For their synthesis, chemists traditionally eithe...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?

Familial hypercholesterolemia is characterized by high LDL cholesterol and an elevated risk to develop coronary heart disease. Mutations in LDL receptor-mediated cholesterol uptake are the main cause ...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product ...

The complete mitochondrial genome of the Dutch elm disease fungus Ophiostoma novo-ulmi subspecies novo-ulmi.

Ophiostoma novo-ulmi, a member of the Ophiostomatales (Ascomycota) is the causal agents of the current Dutch elm disease pandemic in Europe and North America. The complete mitochondrial genome (mtDNA)...

Clinical Trials [573 Associated Clinical Trials listed on BioPortfolio]

Evaluating Therapeutic Response to Novo-TTF

This study is to assess the utility of high resolution 3D echo planar magnetic resonance spectroscopy (3D EPSI) in monitoring Novo-TTF response in glioblastoma multiforme (GBM) patients.

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions

The study will enroll patients with angiographically significant coronary de novo lesions. Subjects will be randomized 1:1 and treated with a Lutonix catheter either before or after bare-m...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Companies [1369 Associated Companies listed on BioPortfolio]

Novo A/S

Novo A/S is fully owned by the Novo Nordisk Foundation and is the holding company of the Novo Group. Novo A/S is a private limited liability company and the majority shareholder in the publicly listed...

Novo Nordisk A/S

Novo A/S, the holding company of the Novo Group, is fully owned by the Novo Nordisk Foundation and was established to manage the Foundation's funds and to invest actively in other companies. What make...

De Novo Pharmaceuticals

The commercial focus of De Novo is the exploitation of human genomics in drug discovery through in silico drug design. The company attracted £2 million financing in a first VC-backed investment roun...

Novo Nordisk, Inc.

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy...

De Novo Pharmaceuticals Ltd

The volume of structural protein data that will emerge in the next few years will serve as a driver that transforms the pharmaceutical industry. Over the next decade it is predicted that the high-reso...

More Information about "De Novo Pharmaceuticals Ltd" on BioPortfolio

We have published hundreds of De Novo Pharmaceuticals Ltd news stories on BioPortfolio along with dozens of De Novo Pharmaceuticals Ltd Clinical Trials and PubMed Articles about De Novo Pharmaceuticals Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of De Novo Pharmaceuticals Ltd Companies in our database. You can also find out about relevant De Novo Pharmaceuticals Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Corporate Database Quicklinks



Searches Linking to this Company Record